Current medical aspects of pantethine: Treatment strategies

Ideggyogyaszati Szemle

Volumn 62, Issue 7-8, 2009, Pages 220-229

  Horvath, Zoltan ^a   Vecsei, Laszlo ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antioxidant; Atherosclerosis; Lipids; Pantethine; Platelets

Indexed keywords

ALCOHOL; CLOFIBRATE; COENZYME A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MERCAPTAMINE; PANTETHINE; PANTOTHENIC ACID; ACETYLCHOLINE; ANTILIPEMIC AGENT; ANTIOXIDANT; CYSTINE; DRUG DERIVATIVE; FATTY ACID; PANTETHEINE; PYRUVIC ACID DERIVATIVE;

ANTIOXIDANT ACTIVITY; CATARACT; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CYSTINOSIS; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; ANIMAL; ATHEROSCLEROSIS; BIOSYNTHESIS; CARBOHYDRATE DIET; CHEMICALLY INDUCED DISORDER; CHEMISTRY; LIPID PEROXIDATION; METABOLISM; OXIDATION REDUCTION REACTION;

ACETYLCHOLINE; ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; BLOOD PLATELETS; CATARACT; CENTRAL NERVOUS SYSTEM; COENZYME A; CYSTINE; CYSTINOSIS; DIETARY CARBOHYDRATES; FATTY ACIDS; HUMANS; HYPERLIPIDEMIAS; LIPID PEROXIDATION; OXIDATION-REDUCTION; PANTETHEINE; PANTOTHENIC ACID; PYRUVATES;

EID: 70349248026     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Williams LW, Hoff-Jorgensen E, Snell EE. Determination and properties of an unidentified growth factor required by Lactobacilus bulgaricus. J Biol Chem 1949;177:933-40.
2. Snell ES, Brown GM. Pantethine and related forms of the Lactobacillus bulgaricus factor. Adv Enzymol Relat Subj Biochem 1953;14:49-71.
3. Hoagland M, Novelli GD. Biosynthesis of coenzyme A from phospho-pantetheine and of pantetheine from panthenate. J Biol Chem 1954;207:767-73.
4. Hiramatsu K, Nozaki H, Arimori S. Influence of pantethine on platelet volume, microviscosity, lipid composition and functions in diabetes mellitus with hyperlipidemia. Tokai J Exp Clin Med 1981;6:49-57. (Pubitemid 11073384)
5. Ranganathan S, Jackson RL, Harmony JA. Effect of pantethine on the biosynthesis of cholesterol in human skin fibroblasts. Atherosclerosis 1982;44:261-73. (Pubitemid 12029359)
6. Butler JD, Zatz M. Pantethine depletes cystinotic fibroblasts of cystine. J Pediatr 1983;102:796-8. (Pubitemid 13089422)
7. Butler JD, Zatz M. Pantethine and cystamine deplete cystine from cystinotic fibroblasts via efflux of cysteaminecystine mixed disulfide. J Clin Invest 1984;74:411-6. (Pubitemid 14053987)
8. Prisco D, Rogasi PG, Matucci M, Abbate R, Genisini GF. Effect of pantethine treatment on platelet aggregation and thromboxane A2 production. Curr Ther Res 1984;35:700-6.
9. Bertolini S, Donati C, Elicio N, Daga A, Cuzzolaro S, Marcenaro A, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol 1986;24:630-7. (Pubitemid 17185917)
10. Arsenio L, Bodria P, Magnati G, Strata A, Trovato R. Effectiveness of long-term treatment with pantethine in patients with dyslipidemia. Clin Ther 1986;8:537-45. (Pubitemid 16014061)
11. Miccoli R, Marchetti P, Sampietro T, Benzi L, Tognarelli M, Navalesi R. Effects of pantethine on lipids and apolipoproteins in hypercholesterolemic diabetic and non-diabetic patients. Curr Ther Res 1984;36:545-49. (Pubitemid 15136657)
12. Vaccarino V, Sirtori M, Gianfranceschi G, Calabresi L, Apebe P, Donati C, et al. Treatment of type III hyperlipiopoteinemia with pantethine partial correction of the biochemical defect. Curr Ther Res 1987;42:1151-6. (Pubitemid 18030371)
13. McRae MP. Treatment of hyperlipoproteinemia with pantethine: A review and analysis of efficacy and tolerability. Nutr Res 2005;25:319-33. (Pubitemid 40488760)
14. Newland MC, Rivera-Calimlim L, Weiss B. Pantothenic acid reverses behavioral effects of ethanol in squirrel monkeys. Fed Proc 1984;46:1130.
15. Newland MC, Rivera-Calimlim L, Weiss B. Interactions between ethanol and pantothenic acid on tremor and behavior in squirrel monkeys. J Stud Alcohol 1992;53:80-5.
16. Bon GB, Cazzolato G, Zago S, Avogaro P. Effects of pantethine on in-vitro peroxidation of low density lipoproteins. Atherosclerosis 1985;57:99-106. (Pubitemid 15247042)
17. Cighetti G, Del Puppo M, Paroni R, Fiorica E, Galli Kienle M. Pantethine inhibits cholesterol and fatty acid synthesis and stimulates carbon dioxide formation in isolated rat hepatocytes. J Lipid Res 1987;28:152-61. (Pubitemid 17036823)
18. Vécsei L, Widerlöv E, Ekman R, Alling C. Cysteamine and pantethine effects on passive avoidance behavior, shuttle box learning, open-field activity, striatal catecholamines and somatostatin. Arch Int Pharmacodyn Ther 1989;299:14-27. (Pubitemid 19192693)
19. Vécsei L, Widerlöv E. Preclinical and clinical studies with cysteamine and pantethine related to the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:835-62. (Pubitemid 20373157)
20. Vécsei L, Widerlöv E, Alling C. Effects of pantethine, cysteamine and pantothenic acid on open-field behavior and brain catecholamines in rats. Arch Int Pharmacodyn Ther 1989;300:14-21. (Pubitemid 20000042)
21. Vécsei L, Alling C, Heilig M, Widerlöv E. Effects of cysteamine and pantethine on open-field behavior, hypothalamic catecholamine concentrations, and somatostatin-induced barrel rotation in rats. Pharmacol Biochem Behav 1989;32:629-35. (Pubitemid 19162380)
22. Vécsei L, Widerlöv E, Alling C. Comparative studies of intracerebroventricularly administered cysteamine and pantethine in different behavioral tests and on brain catecholamines in rats. Arch Int Pharmacodyn Ther 1990;305:140-51.
23. Vécsei L, Alling C, Heilig M, Widerlöv E. Dose- and time-response effects of pantethine on open-field behavior, and on central neurotransmission in rats. Pharmacol Biochem Behav 1990;35:165-70. (Pubitemid 20034582)
24. Tsai SJ. Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels. Med Hypotheses 2006;67:1185-8.
25. Ono S, Kameda K, Abiko Y. Metabolism of panthethine in the rat. J Nutr Sci Vitaminol 1974;20:203-13.
26. Branca D, Scutari G, Siliprandi N. Pantethine and pantothenate effect on the CoA content of rat liver. Int J Vitam Nutr Res 1984;54:211-6.
27. Cighetti G, Del Puppo M, Paroni R, Galli Kienle M. Modulation of HMG-CoA reductase activity by pantetheine/pantethine. Biochim Biophys Acta 1988;963:389-93. (Pubitemid 18266716)
28. McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Med Hypotheses 2001;56:314-7. (Pubitemid 32382348)
29. Carrara P, Matturri L, Galbussera M, Lovati MR, Franceschini G, Sirtori CR. Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. Atherosclerosis 1984;53:255-64.
30. Farina R, Lovati MR, Raucci G, Sirtori CR. Effects of pantethine on different models of experimental hyperlipidemia in rodents: A comparison with clofibrate. Pharmacol Res Comm 1982;14:499-510. (Pubitemid 12033712)
31. Tomikawa M, Nakayasu T, Tawara K, Kameda KY, Abiko Y. Effect of pantethine on lipoprotein profiles and HDL subfractions in experimentally hypercholesterolemic rabbits. Atherosclerosis 1982;41:267-77. (Pubitemid 12213357)
32. Tawara K, Ishihara M, Ogawa H, Tomikawa M. Effect of probucol, pantethine and their combinations on serum lipoprotein metabolism and on the incidence of atheromatous lesions in the rabbit. Jpn J Pharmacol 1986;41:211-22. (Pubitemid 16078708)
33. Shattil SJ, Cooper RA. Membrane microviscosity and human platelet function. Biochemistry 1976;15:4832-7.
34. Shastri KM, Carvalho AC, Lees RS. Platelet function and platelet lipid composition in the dyslipoproteinemias. J Lipid Res 1980;21:467-72. (Pubitemid 11235483)
35. Bon GB, Ballerini PF, Pitted G, Avogaro P. In vitro effect of pantethine on platelet aggregation. Curr Ther Res 1986;40:464-70.
36. Hofmann B, Lang A, Ostermann G, Arese P, Biffignandi P, Till U. Effect of pantethine on platelet functions in vitro. Curr Ther Res 1987;41:761-801.
37. Jeitner TM, Oliver JR. The depletion of plasma prolactin by pantethine in oestrogen-primed hyperprolactinaemic rats. J Endocrinol 1990;124:397-402. (Pubitemid 20070446)
38. Agrati AM, Ambrosi G, Ferraro G, Palmieri G. Gemfibrozil efficacy vs pantethine in dyslipoproteinemic patients: A controlled study. Curr Ther Res 1989;45:650-63. (Pubitemid 19114046)
39. Cattin L, DaCol P, Fonda M, Mameli M, Pilotto L, Vanuzzo D. Treatment of hypercholesterolemia with pantethine and fenofibrate: an open randomized study on 43 subjects. Curr Ther Res 1985;38:386-95.
40. Postiglione A, Rubba P, Cicerano U, Chierchia I, Mancini M. Pantethine versus fenofibrate in the treatment of type II hyperlipoproteinemia. Monogr Atheroscler 1985;13:145-8.
41. Tonutti L, Taboga C, Noacco C. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia.] (article in Italian) Minerva Med 1991;82:657-63.
42. DaCol P, Cattin L, Fonda M, Mameli M, Feruglio F. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol. Curr Ther Res 1984;36:314-21.
43. Pins JJ, Keenan JM. Dietary and nutraceutical options for managing the hypertriglyceridemic patient. Prog Cardiovasc Nurs 2006;21:89-93.
44. Jeitner TM, Oliver JR. Effect of cysteamine on the lysosomal enzymes of the hyperprolactinaemic rat pituitary. J Endocrinol 1990;125:75-80. (Pubitemid 20129791)
45. Ong GL, Miaskowski C, Haldar J. Changes in oxytocin and vasopressin content in posterior pituitary and hypothalamus following pantethine treatment. Life Sci 1990;47:503-6.
46. Reichlin S, Bollinger-Gruber JA. Pantethine, a cysteamine precursor, depletes immunoreactive somatostatin and prolactin in the rat. Endocrinology 1985;117:492-5. (Pubitemid 15237860)
47. Sellini M, Sartori M, Baccarini S, Bassi R. [Various hormonal parameters (ACTH, cortisol, somatotropic hormone and prolactin), following administration of a single high dose of pantethine in healthy subjects.] (article in Italian) Boll Soc Ital Biol Sper 1987;63:143-5.
48. Abucham J, Bollinger-Gruber J, Reichlin S. Pantethine, a somatostatin depleting agent, increases food intake in rats. Pharmacol Biochem Behav 1989;33:585-9. (Pubitemid 19237532)
49. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002;8:143-9. (Pubitemid 34155125)
50. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-50. (Pubitemid 35379064)
51. Borrell-Pagès M, Canals JM, Cordelières FP, Parker JA, Pineda JR, Grange G, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410-24.
52. Penet MF, Abou-Hamdan M, Coltel N, Cornille E, Grau GE, de Reggi M, et al. Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci USA 2008;105:1321-6. (Pubitemid 351397051)
53. Nagiel-Ostaszewski I, Lau-Cam CA. Protection by pantethine, pantothenic acid and cystamine against carbon tetrachloride-induced hepatotoxicity in the rat. Res Commun Chem Pathol Pharmacol 1990;67:289-92. (Pubitemid 20098127)
54. Orloff S, Butler JD, Towne D, Mukherjee AB, Schulman JD. Pantetheinase activity and cysteamine content in cystinotic and normal fibroblast and leukocytes. Pediatr Res 1981;15:1063-7. (Pubitemid 11087059)
55. Wittwer CT, Gahl WA, Butler JD, Zatz M, Thoene JG. Metabolism of pantethine in cystinosis. J Clin Invest 1985;76:1665-72. (Pubitemid 16193590)
56. Rivera-Calimlim L, Hartley D, Osterhout D. Effect of ethanoi and pantothenic acid on brain acetylcholine synthesis. Br J Pharmacol 1988;95:77-82.
57. Watanabe A, Hobara N, Kobayashi M, Nakatsukasa H, Nagashima H. Lowering of blood acetaldehyde but not ethanoi concentrations by pantethine following alcohol ingestion: different effects in flushing and nonflushing subjects. Alcohol Clin Exp Res 1985;9:272-6. (Pubitemid 15011404)
58. Watanabe A, Hobara N, Nagashima H. Activation and inhibition of yeast aldehyde dehydrogenase activity by pantethine and its metabolites. Ann Nutr Metab 1986;30:54-7.
59. Clark JI, Livesey JC, Steele JE. Delay or inhibition of rat lens opacification using pantethine and WR-77913. Exp Eye Res 1996;62:75-84. (Pubitemid 26135475)
60. Hiraoka T, Clark JI, Li XY, Thurston GM. Effect of selected anti-cataract agents on opacification in the selenite cataract model. Exp Eye Res 1996;62:11-9. (Pubitemid 26139784)
61. Congdon NT, West ST, Duncan DT, Fisher DT, Vitale ST, Rieger KT, et al. The effect of pantethine and ultraviolet-B radiation on the development of lenticular opacity in the emory mouse. Curr Eye Res 2000;20:17-24.
62. Hiraoka T, Clark JI. Inhibition of lens opacification during the early stages of cataract formation. Invest Ophthalmol Vis Sci 1995;36:2550-5.
63. Friberg G, Pande J, Ogun O, Benedek GB. Pantethine inhibits the formation of high-Tc protein aggregates in gamma B crystallin solutions. Curr Eye Res 1996;15:1182-90.
64. Barton-Wright EC, Elliott WA. The pantothenic acid metabolism of rheumatoid arthritis. Lancet 1963;2:862-3.
65. General Practitioner Research Group. Calcium pantothenate in arthritic conditions. A report from the General Practitioner Research Group. Practitioner 1980;224:208-11.